<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389701</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000509044</org_study_id>
    <secondary_id>SPARROW-I071-341-03</secondary_id>
    <secondary_id>SPARROW-IRB-6016</secondary_id>
    <nct_id>NCT00389701</nct_id>
  </id_info>
  <brief_title>Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment</brief_title>
  <official_title>Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sparrow Regional Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy,&#xD;
      such as dexamethasone, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving bortezomib together with&#xD;
      dexamethasone may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with&#xD;
      dexamethasone works in treating patients with multiple myeloma that has relapsed or has not&#xD;
      responded to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the overall response rate (complete response and partial response) in patients&#xD;
           with relapsed or refractory multiple myeloma treated with induction therapy and&#xD;
           maintenance therapy comprising bortezomib and dexamethasone.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine time to progression in patients treated with this regimen.&#xD;
&#xD;
        -  Determine overall and progression-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
        -  Induction therapy: Patients receive bortezomib IV on days 1, 4, 8, and 11. Patients also&#xD;
           receive oral dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every&#xD;
           21 days for 4 courses. Patients who achieve complete response (CR) receive an additional&#xD;
           2 courses of induction therapy and proceed to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Patients receive bortezomib IV on days 1, 8, 15, and 22. Patients&#xD;
           also receive oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment&#xD;
           repeats every 36 days in the absence of disease progression or unacceptable toxicity.&#xD;
           Patients who achieve CR receive an additional 2 courses of maintenance therapy beyond&#xD;
           documentation of CR.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response after completion of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and progression-free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma&#xD;
&#xD;
               -  Refractory or relapsed disease meeting the following criteria:&#xD;
&#xD;
                    -  Primary refractory disease and first-line relapsing disease&#xD;
&#xD;
                    -  Progressive disease after last therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³ (≥ 30,000/mm³ for patients with significant bone marrow&#xD;
             involvement)&#xD;
&#xD;
               -  Transfusions allowed&#xD;
&#xD;
          -  Hemoglobin ≥ 7.5 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 750/mm³&#xD;
&#xD;
          -  Serum calcium &lt; 14 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2 within the past 14 days&#xD;
&#xD;
          -  No hypersensitivity to boron or mannitol&#xD;
&#xD;
          -  No cardiovascular complications, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class III-IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina&#xD;
&#xD;
               -  Ventricular arrhythmias&#xD;
&#xD;
               -  Electrocardiographic evidence of acute ischemia or active conduction system&#xD;
                  abnormalities&#xD;
&#xD;
               -  Cardiac amyloidosis&#xD;
&#xD;
          -  No other cancer or treatment for cancer other than basal cell cancer of the skin&#xD;
             within the past 5 years&#xD;
&#xD;
          -  No poorly controlled chronic diseases (e.g., diabetes mellitus or hypertension)&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No hepatitis B surface antigen or active hepatitis C infection&#xD;
&#xD;
          -  No active systemic infection requiring therapy&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would interfere with study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No plasmapheresis within the past 4 weeks&#xD;
&#xD;
          -  No major surgery within the past 4 weeks&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No chemotherapy (e.g., clarithromycin) within the past 4 weeks&#xD;
&#xD;
          -  No radiotherapy within the past 3 weeks&#xD;
&#xD;
          -  No corticosteroids (&gt; 10 mg/day of prednisone or equivalent) within the past 3 weeks&#xD;
&#xD;
          -  No other immunotherapy within the past 8 weeks&#xD;
&#xD;
          -  No other investigational drugs within the past 14 days&#xD;
&#xD;
          -  No concurrent participation in other clinical research studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordan Srkalovic, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sparrow Regional Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sparrow Regional Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48909-7980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gordan Srkalovic, MD, PhD</last_name>
      <phone>517-364-2467</phone>
      <email>gordan.srkalovic@sparrow.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Gordan Srkalovic</name_title>
    <organization>Sparrow Regional Cancer Center</organization>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

